Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival-Reference-Cited by-同舟云学术

Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival

Published:2022-07 Issue:5 Volume:23 Page:e321-e324
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Nagata Shunichi^ORCID,Hamaji Masatsugu,Ozasa Hiroaki,Yamada Yoshito,Ohsumi Akihiro,Date Hiroshi

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference7 articles.

1. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

3. Salvage surgery after chemotherapy or chemoradiotherapy for initially unresectable lung carcinoma;Sonobe;Ann Thorac Surg,2019

4. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors;Bott;Ann Thorac Surg,2018

5. Salvage thoracoscopic resection after nivolumab for stage IV;Hamaji;Asian Cardiovasc Thorac Ann,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery;Surgery Today;2024-03-14

2. Salvage pleurectomy/decortication following immunotherapy for malignant pleural mesothelioma;Interdisciplinary CardioVascular and Thoracic Surgery;2023-11-15

3. Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer;Lung Cancer;2023-08

4. Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity;BMJ Case Reports;2022-12

5. Antineoplastics;Reactions Weekly;2022-07